APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid
tumors and secures manufacturing for upcoming clinical trials.

Press release (EN) | Presseaussendung (DE)